Equities research analysts at Wedbush assumed coverage on shares of Apogee Therapeutics (NASDAQ:APGE – Get Free Report) in a research note issued to investors on Tuesday, Briefing.com reports. The firm set an “outperform” rating and a $40.00 price target on the stock. Wedbush’s target price would suggest a potential upside of 95.12% from the stock’s […]
Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report)’s share price hit a new 52-week high during trading on Tuesday . The company traded as high as $21.99 and last traded at $21.45, with a volume of 95145 shares. The stock had previously closed at $20.50. Analyst Upgrades and Downgrades Several equities analysts have weighed in […]
Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) Director Nimish P. Shah purchased 1,750,000 shares of the stock in a transaction dated Thursday, July 13th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $29,750,000.00. Following the transaction, the director now owns 1,750,000 shares in the company, […]
Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) Director Nimish P. Shah bought 1,750,000 shares of the stock in a transaction that occurred on Thursday, July 13th. The shares were purchased at an average price of $17.00 per share, with a total value of $29,750,000.00. Following the purchase, the director now owns 1,750,000 shares of […]